Literature DB >> 23500189

Optimization and characterization of a rat model of prostate cancer-induced bone pain using behavioral, pharmacological, radiological, histological and immunohistochemical methods.

Arjun Muralidharan1, Bruce D Wyse, Maree T Smith.   

Abstract

The major limitation of currently utilized rodent models of prostate cancer (PCa)-induced bone pain (PCIBP) involving intra-osseous injection of PCa cells, is their relatively short-term applicability due to progressive deterioration of animal health necessitating euthanasia. Here, we describe establishment of an optimized rat model of PCIBP where good animal health was maintained for at least 90-days following unilateral intra-tibial injection (ITI) of PCa cells. We have characterized this model using behavioral, pharmacological, radiological, histological and immunohistochemical methods. Our findings show that following unilateral ITI of 4×10(4) AT3B PCa cells (APCCs), there was temporal development of bilateral hindpaw hypersensitivity that was fully developed between days 14 and 21 post-ITI. Although there was apparent spontaneous reversal of bilateral hindpaw sensitivity that was maintained until at least day 90 post-ITI, administration of bolus doses of the opioid receptor antagonist, naloxone, rescued the pain phenotype in these animals. Hence, upregulation of endogenous opioid signaling mechanisms appears to underpin apparent spontaneous resolution of hindpaw hypersensitivity. Importantly, the histological and radiological assessments confirmed that tumor formation and development of osteosclerotic metastases was confined to the APCC-injected tibial bones. In our rat model of PCIBP, single bolus doses of morphine, gabapentin, meloxicam and amitriptyline produced dose-dependent relief of mechanical allodynia and thermal hyperalgesia in the bilateral hindpaws. The optimized rat model of PCIBP characterized herein has potential to provide new insights into the pathophysiological mechanisms associated with long-term (mal)adaptive pain due to advanced PCa-induced bony metastases and for screening novel compounds with potential for improved alleviation of this condition.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23500189     DOI: 10.1016/j.pbb.2013.02.020

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  8 in total

Review 1.  Glycinergic Modulation of Pain in Behavioral Animal Models.

Authors:  Julian M Peiser-Oliver; Sally Evans; David J Adams; Macdonald J Christie; Robert J Vandenberg; Sarasa A Mohammadi
Journal:  Front Pharmacol       Date:  2022-05-25       Impact factor: 5.988

Review 2.  Using animal models to understand cancer pain in humans.

Authors:  Gillian L Currie; Emily S Sena; Marie T Fallon; Malcolm R Macleod; Lesley A Colvin
Journal:  Curr Pain Headache Rep       Date:  2014-06

3.  Comparison of Burrowing and Stimuli-Evoked Pain Behaviors as End-Points in Rat Models of Inflammatory Pain and Peripheral Neuropathic Pain.

Authors:  Arjun Muralidharan; Andy Kuo; Meera Jacob; Jacintha S Lourdesamy; Lara Melo Soares Pinho De Carvalho; Janet R Nicholson; Laura Corradini; Maree T Smith
Journal:  Front Behav Neurosci       Date:  2016-05-10       Impact factor: 3.558

4.  Establishment and Characterization of a Novel Rat Model of Mechanical Low Back Pain Using Behavioral, Pharmacologic and Histologic Methods.

Authors:  Arjun Muralidharan; Thomas S W Park; John T Mackie; Luiz G S Gimenez; Andy Kuo; Janet R Nicholson; Laura Corradini; Maree T Smith
Journal:  Front Pharmacol       Date:  2017-07-27       Impact factor: 5.810

Review 5.  The Walker 256 Breast Cancer Cell- Induced Bone Pain Model in Rats.

Authors:  Priyank A Shenoy; Andy Kuo; Irina Vetter; Maree T Smith
Journal:  Front Pharmacol       Date:  2016-08-31       Impact factor: 5.810

Review 6.  Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.

Authors:  Arjun Muralidharan; Maree T Smith
Journal:  Inflammopharmacology       Date:  2013-08-06       Impact factor: 4.473

7.  Optimization and In Vivo Profiling of a Refined Rat Model of Walker 256 Breast Cancer Cell-Induced Bone Pain Using Behavioral, Radiological, Histological, Immunohistochemical and Pharmacological Methods.

Authors:  Priyank Shenoy; Andy Kuo; Irina Vetter; Maree T Smith
Journal:  Front Pharmacol       Date:  2017-07-06       Impact factor: 5.810

8.  The Somatostatin Receptor-4 Agonist J-2156 Alleviates Mechanical Hypersensitivity in a Rat Model of Breast Cancer Induced Bone Pain.

Authors:  Priyank A Shenoy; Andy Kuo; Nemat Khan; Louise Gorham; Janet R Nicholson; Laura Corradini; Irina Vetter; Maree T Smith
Journal:  Front Pharmacol       Date:  2018-05-15       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.